Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

December 1, 2024

Study Completion Date

December 1, 2025

Conditions

Solid TumorLymphoma

Interventions

DRUG

SHR2554+SHR1701

SHR2554: recommended dose from phase I trial, PO, twice a day. SHR1701: 30mg/kg, IV, over 30 minutes

DRUG

SHR1701

SHR1701: 30mg/kg, IV, over 30 minutes

Trial Locations (1)

RECRUITING

Department of Biotherapeutic, Chinese PLA General Hospital, Beijing

All Listed Sponsors

lead

Chinese PLA General Hospital

OTHER